ID   PNPO_HUMAN              Reviewed;         261 AA.
AC   Q9NVS9; B4E0V0; B4E152; B4E1D7; D3DTT9;
DT   26-SEP-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   10-MAY-2017, entry version 158.
DE   RecName: Full=Pyridoxine-5'-phosphate oxidase;
DE            EC=1.4.3.5;
DE   AltName: Full=Pyridoxamine-phosphate oxidase;
GN   Name=PNPO;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Kwon O.-S.;
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4).
RC   TISSUE=Liver, Teratocarcinoma, Thymus, and Thyroid;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-238 AND SER-241, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 49-161 IN COMPLEX WITH FMN
RP   AND PYRIDOXAL 5'-PHOSPHATE, PARTIAL PROTEIN SEQUENCE, SUBUNIT, ENZYME
RP   REGULATION, FUNCTION, AND COFACTOR.
RX   PubMed=12824491; DOI=10.1110/ps.0356203;
RA   Musayev F.N., Di Salvo M.L., Ko T.-P., Schirch V., Safo M.K.;
RT   "Structure and properties of recombinant human pyridoxine 5'-phosphate
RT   oxidase.";
RL   Protein Sci. 12:1455-1463(2003).
RN   [10]
RP   VARIANT PNPOD TRP-229, AND VARIANT LYS-50.
RX   PubMed=15772097; DOI=10.1093/hmg/ddi120;
RA   Mills P.B., Surtees R.A.H., Champion M.P., Beesley C.E., Dalton N.,
RA   Scambler P.J., Heales S.J.R., Briddon A., Scheimberg I.,
RA   Hoffmann G.F., Zschocke J., Clayton P.T.;
RT   "Neonatal epileptic encephalopathy caused by mutations in the PNPO
RT   gene encoding pyridox(am)ine 5'-phosphate oxidase.";
RL   Hum. Mol. Genet. 14:1077-1086(2005).
RN   [11]
RP   VARIANT PNPOD HIS-225.
RX   PubMed=27864847; DOI=10.1002/humu.23149;
RG   Clinical Study Group;
RA   Parrini E., Marini C., Mei D., Galuppi A., Cellini E., Pucatti D.,
RA   Chiti L., Rutigliano D., Bianchini C., Virdo S., De Vita D.,
RA   Bigoni S., Barba C., Mari F., Montomoli M., Pisano T., Rosati A.,
RA   Guerrini R.;
RT   "Diagnostic targeted resequencing in 349 patients with drug-resistant
RT   pediatric epilepsies identifies causative mutations in 30 different
RT   genes.";
RL   Hum. Mutat. 38:216-225(2017).
CC   -!- FUNCTION: Catalyzes the oxidation of either pyridoxine 5'-
CC       phosphate (PNP) or pyridoxamine 5'-phosphate (PMP) into pyridoxal
CC       5'-phosphate (PLP). {ECO:0000269|PubMed:12824491}.
CC   -!- CATALYTIC ACTIVITY: Pyridoxamine 5'-phosphate + H(2)O + O(2) =
CC       pyridoxal 5'-phosphate + NH(3) + H(2)O(2).
CC   -!- CATALYTIC ACTIVITY: Pyridoxine 5'-phosphate + O(2) = pyridoxal 5'-
CC       phosphate + H(2)O(2).
CC   -!- COFACTOR:
CC       Name=FMN; Xref=ChEBI:CHEBI:58210;
CC         Evidence={ECO:0000269|PubMed:12824491};
CC       Note=Binds 1 FMN per subunit. {ECO:0000269|PubMed:12824491};
CC   -!- PATHWAY: Cofactor metabolism; pyridoxal 5'-phosphate salvage;
CC       pyridoxal 5'-phosphate from pyridoxamine 5'-phosphate: step 1/1.
CC   -!- PATHWAY: Cofactor metabolism; pyridoxal 5'-phosphate salvage;
CC       pyridoxal 5'-phosphate from pyridoxine 5'-phosphate: step 1/1.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:12824491}.
CC   -!- INTERACTION:
CC       Q6RW13-2:AGTRAP; NbExp=5; IntAct=EBI-11030787, EBI-11522760;
CC       Q96DZ9-2:CMTM5; NbExp=3; IntAct=EBI-11030787, EBI-11522780;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q9NVS9-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NVS9-2; Sequence=VSP_058769, VSP_058770;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay. No
CC         experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q9NVS9-3; Sequence=VSP_056410;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=Q9NVS9-4; Sequence=VSP_056411;
CC         Note=No experimental confirmation available.;
CC   -!- DISEASE: Pyridoxine-5'-phosphate oxidase deficiency (PNPOD)
CC       [MIM:610090]: The main feature of neonatal epileptic
CC       encephalopathy is the onset within hours of birth of a severe
CC       seizure disorder that does not respond to anticonvulsant drugs and
CC       can be fatal. Seizures can cease with the administration of PLP,
CC       being resistant to treatment with pyridoxine,.
CC       {ECO:0000269|PubMed:15772097, ECO:0000269|PubMed:27864847}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the pyridoxamine 5'-phosphate oxidase
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG64562.1; Type=Erroneous translation; Note=Wrong choice of frame.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF468030; AAM76918.1; -; mRNA.
DR   EMBL; AK001397; BAA91668.1; -; mRNA.
DR   EMBL; AK303536; BAG64562.1; ALT_SEQ; mRNA.
DR   EMBL; AK303665; BAG64664.1; -; mRNA.
DR   EMBL; AK303792; BAG64749.1; -; mRNA.
DR   EMBL; CH471109; EAW94770.1; -; Genomic_DNA.
DR   EMBL; CH471109; EAW94771.1; -; Genomic_DNA.
DR   EMBL; BC006525; AAH06525.1; -; mRNA.
DR   CCDS; CCDS11522.1; -. [Q9NVS9-1]
DR   RefSeq; NP_060599.1; NM_018129.3. [Q9NVS9-1]
DR   RefSeq; XP_011523270.1; XM_011524968.2.
DR   UniGene; Hs.631742; -.
DR   PDB; 1NRG; X-ray; 1.95 A; A=1-261.
DR   PDB; 3HY8; X-ray; 2.50 A; A=1-261.
DR   PDBsum; 1NRG; -.
DR   PDBsum; 3HY8; -.
DR   DisProt; DP00168; -.
DR   ProteinModelPortal; Q9NVS9; -.
DR   SMR; Q9NVS9; -.
DR   BioGrid; 120463; 23.
DR   IntAct; Q9NVS9; 4.
DR   STRING; 9606.ENSP00000225573; -.
DR   BindingDB; Q9NVS9; -.
DR   ChEMBL; CHEMBL3271932; -.
DR   DrugBank; DB03345; Beta-Mercaptoethanol.
DR   DrugBank; DB00114; Pyridoxal Phosphate.
DR   DrugBank; DB02209; Pyridoxine-5'-Phosphate.
DR   DrugBank; DB03247; Riboflavin Monophosphate.
DR   iPTMnet; Q9NVS9; -.
DR   PhosphoSitePlus; Q9NVS9; -.
DR   BioMuta; PNPO; -.
DR   DMDM; 37082126; -.
DR   REPRODUCTION-2DPAGE; IPI00018272; -.
DR   EPD; Q9NVS9; -.
DR   PaxDb; Q9NVS9; -.
DR   PeptideAtlas; Q9NVS9; -.
DR   PRIDE; Q9NVS9; -.
DR   Ensembl; ENST00000225573; ENSP00000225573; ENSG00000108439. [Q9NVS9-1]
DR   Ensembl; ENST00000434554; ENSP00000399960; ENSG00000108439. [Q9NVS9-4]
DR   Ensembl; ENST00000582171; ENSP00000463994; ENSG00000108439. [Q9NVS9-2]
DR   Ensembl; ENST00000585320; ENSP00000462345; ENSG00000108439. [Q9NVS9-2]
DR   GeneID; 55163; -.
DR   KEGG; hsa:55163; -.
DR   UCSC; uc010wlb.3; human. [Q9NVS9-1]
DR   CTD; 55163; -.
DR   DisGeNET; 55163; -.
DR   GeneCards; PNPO; -.
DR   HGNC; HGNC:30260; PNPO.
DR   HPA; HPA023204; -.
DR   HPA; HPA027776; -.
DR   MalaCards; PNPO; -.
DR   MIM; 603287; gene.
DR   MIM; 610090; phenotype.
DR   neXtProt; NX_Q9NVS9; -.
DR   OpenTargets; ENSG00000108439; -.
DR   Orphanet; 79096; Pyridoxal phosphate-responsive seizures.
DR   PharmGKB; PA134915565; -.
DR   eggNOG; KOG2586; Eukaryota.
DR   eggNOG; COG0259; LUCA.
DR   GeneTree; ENSGT00390000011219; -.
DR   HOGENOM; HOG000242755; -.
DR   HOVERGEN; HBG045634; -.
DR   KO; K00275; -.
DR   OMA; PEHWGGY; -.
DR   OrthoDB; EOG091G0J0R; -.
DR   PhylomeDB; Q9NVS9; -.
DR   TreeFam; TF313411; -.
DR   BioCyc; MetaCyc:HS03105-MONOMER; -.
DR   Reactome; R-HSA-964975; Vitamins B6 activation to pyridoxal phosphate.
DR   SABIO-RK; Q9NVS9; -.
DR   UniPathway; UPA01068; UER00304.
DR   UniPathway; UPA01068; UER00305.
DR   ChiTaRS; PNPO; human.
DR   EvolutionaryTrace; Q9NVS9; -.
DR   GeneWiki; PNPO; -.
DR   GenomeRNAi; 55163; -.
DR   PRO; PR:Q9NVS9; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000108439; -.
DR   CleanEx; HS_PNPO; -.
DR   ExpressionAtlas; Q9NVS9; baseline and differential.
DR   Genevisible; Q9NVS9; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0010181; F:FMN binding; IDA:CAFA.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:CAFA.
DR   GO; GO:0030170; F:pyridoxal phosphate binding; IDA:CAFA.
DR   GO; GO:0004733; F:pyridoxamine-phosphate oxidase activity; IDA:CAFA.
DR   GO; GO:0042823; P:pyridoxal phosphate biosynthetic process; IDA:CAFA.
DR   GO; GO:0008615; P:pyridoxine biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0042816; P:vitamin B6 metabolic process; TAS:Reactome.
DR   Gene3D; 2.30.110.10; -; 1.
DR   HAMAP; MF_01629; PdxH; 1.
DR   InterPro; IPR000659; Pyridox_Oxase.
DR   InterPro; IPR019740; Pyridox_Oxase_CS.
DR   InterPro; IPR011576; Pyridox_Oxase_FMN-bd.
DR   InterPro; IPR019576; Pyridoxamine_oxidase_dimer_C.
DR   InterPro; IPR012349; Split_barrel_FMN-bd.
DR   PANTHER; PTHR10851:SF4; PTHR10851:SF4; 1.
DR   Pfam; PF10590; PNPOx_C; 1.
DR   Pfam; PF01243; Pyridox_oxidase; 1.
DR   PIRSF; PIRSF000190; Pyd_amn-ph_oxd; 1.
DR   SUPFAM; SSF50475; SSF50475; 1.
DR   TIGRFAMs; TIGR00558; pdxH; 1.
DR   PROSITE; PS01064; PYRIDOX_OXIDASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Epilepsy; Flavoprotein;
KW   FMN; Oxidoreductase; Phosphoprotein; Polymorphism;
KW   Pyridoxal phosphate; Pyridoxine biosynthesis; Reference proteome.
FT   CHAIN         1    261       Pyridoxine-5'-phosphate oxidase.
FT                                /FTId=PRO_0000167783.
FT   NP_BIND      95     98       FMN. {ECO:0000269|PubMed:12824491}.
FT   NP_BIND     110    111       FMN. {ECO:0000269|PubMed:12824491}.
FT   NP_BIND     116    117       FMN. {ECO:0000269|PubMed:12824491}.
FT   NP_BIND     174    175       FMN. {ECO:0000269|PubMed:12824491}.
FT   REGION       42     45       Pyridoxal 5'-phosphate binding.
FT                                {ECO:0000250|UniProtKB:P0AFI7}.
FT   REGION      225    227       Pyridoxal 5'-phosphate binding.
FT                                {ECO:0000250|UniProtKB:P0AFI7}.
FT   BINDING     100    100       Pyridoxal 5'-phosphate.
FT                                {ECO:0000269|PubMed:12824491}.
FT   BINDING     139    139       FMN. {ECO:0000250|UniProtKB:P0AFI7}.
FT   BINDING     157    157       Pyridoxal 5'-phosphate.
FT                                {ECO:0000269|PubMed:12824491}.
FT   BINDING     161    161       Pyridoxal 5'-phosphate.
FT                                {ECO:0000269|PubMed:12824491}.
FT   BINDING     165    165       Pyridoxal 5'-phosphate.
FT                                {ECO:0000269|PubMed:12824491}.
FT   BINDING     219    219       FMN. {ECO:0000250|UniProtKB:P0AFI7}.
FT   BINDING     229    229       FMN. {ECO:0000250|UniProtKB:P0AFI7}.
FT   MOD_RES     238    238       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     241    241       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ      47     69       AFEETHLTSLDPVKQFAAWFEEA -> RWKTLCSHVAAEGL
FT                                RERWLPLLH (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_058769.
FT   VAR_SEQ      70    261       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_058770.
FT   VAR_SEQ     122    139       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056410.
FT   VAR_SEQ     140    182       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056411.
FT   VARIANT      50     50       E -> K (in dbSNP:rs549477447).
FT                                {ECO:0000269|PubMed:15772097}.
FT                                /FTId=VAR_029358.
FT   VARIANT     116    116       R -> Q (in dbSNP:rs17679445).
FT                                /FTId=VAR_029359.
FT   VARIANT     225    225       R -> H (in PNPOD).
FT                                {ECO:0000269|PubMed:27864847}.
FT                                /FTId=VAR_078229.
FT   VARIANT     229    229       R -> W (in PNPOD; strong activity
FT                                decrease; dbSNP:rs104894629).
FT                                {ECO:0000269|PubMed:15772097}.
FT                                /FTId=VAR_029360.
FT   HELIX        58     71       {ECO:0000244|PDB:1NRG}.
FT   STRAND       80     86       {ECO:0000244|PDB:1NRG}.
FT   STRAND       88     90       {ECO:0000244|PDB:3HY8}.
FT   STRAND       92     98       {ECO:0000244|PDB:1NRG}.
FT   STRAND      102    105       {ECO:0000244|PDB:3HY8}.
FT   STRAND      106    112       {ECO:0000244|PDB:1NRG}.
FT   HELIX       116    123       {ECO:0000244|PDB:1NRG}.
FT   STRAND      126    133       {ECO:0000244|PDB:1NRG}.
FT   HELIX       134    136       {ECO:0000244|PDB:1NRG}.
FT   STRAND      138    148       {ECO:0000244|PDB:1NRG}.
FT   HELIX       151    160       {ECO:0000244|PDB:1NRG}.
FT   HELIX       163    171       {ECO:0000244|PDB:1NRG}.
FT   HELIX       181    194       {ECO:0000244|PDB:1NRG}.
FT   TURN        195    197       {ECO:0000244|PDB:1NRG}.
FT   STRAND      206    211       {ECO:0000244|PDB:1NRG}.
FT   STRAND      214    220       {ECO:0000244|PDB:1NRG}.
FT   STRAND      228    234       {ECO:0000244|PDB:1NRG}.
FT   STRAND      254    258       {ECO:0000244|PDB:1NRG}.
SQ   SEQUENCE   261 AA;  29988 MW;  2C74E9F962FE2A95 CRC64;
     MTCWLRGVTA TFGRPAEWPG YLSHLCGRSA AMDLGPMRKS YRGDREAFEE THLTSLDPVK
     QFAAWFEEAV QCPDIGEANA MCLATCTRDG KPSARMLLLK GFGKDGFRFF TNFESRKGKE
     LDSNPFASLV FYWEPLNRQV RVEGPVKKLP EEEAECYFHS RPKSSQIGAV VSHQSSVIPD
     REYLRKKNEE LEQLYQDQEV PKPKSWGGYV LYPQVMEFWQ GQTNRLHDRI VFRRGLPTGD
     SPLGPMTHRG EEDWLYERLA P
//
